Industry

CHICAGO–(BUSINESS WIRE)–Ventas, Inc. (NYSE: VTR) (“Ventas” or “The Company”) today confirmed that Chairman and CEO Debra A. Cafaro will accept the Women Corporate Directors (WCD) 2022 Visionary Award for Strategic Leadership this evening at the organization’s 11th Annual Visionary Awards Celebration and Gala. WCD is the only global membership organization and community of women corporate … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “BPH Treatment Device Market Size, Share & COVID-19 Impact Analysis | Global | 2022-2028 | MedCore” report has been added to ResearchAndMarkets.com’s offering. The total global BPH treatment device market is growing at a rate of 5.2%, which will take the 2021 market value of $1.2 billion up to $1.7 billion by 2028. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Enzyme Replacement Therapy Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Enzyme Type, Therapeutic Conditions, Route of Administration, and End User” report has been added to ResearchAndMarkets.com’s offering. The enzyme replacement therapy market is expected to grow from US$ 9,673.39 million in 2021 to US$ 15,184.70 million by 2028; it … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “U.S. Assisted Living Facility Market Size, Share & Trends Analysis Report by Age (More Than 85, 75-84, 65-74, Less Than 65), Region (West, South, Midwest), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. assisted living facility market size is expected to reach USD 140.8 billion by 2030 and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “US Pruritus Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Pruritus pipeline products, Pruritus epidemiology, Pruritus market valuations and forecast, Pruritus drugs sales and competitive landscape in the US. The research is classified into seven sections – Pruritus treatment options, pipeline products, … [Read more…]

Strategic Investment Expected to Help Accelerate Cardiac Monitoring and Strategic Relationship Aims to Create Improved Disease State Treatment Models SAN JOSE, Calif.–(BUSINESS WIRE)–#vitalconnect–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the completion of an investment funded by Health Insight Capital, the investment arm of HCA Healthcare Inc., (NYSE: HCA), one … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Aicardi Goutieres Syndrome – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This ‘Aicardi-Goutieres Syndrome (AGS) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Aicardi-Goutieres Syndrome (AGS) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Ventricular Tachycardia (V-tach or VT) – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering. This Ventricular Tachycardia (V-tach or VT) – Pipeline Insight, 2022″ report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Ventricular Tachycardia (V-tach or VT) pipeline landscape. It covers the pipeline drug profiles, including … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Generalized Myasthenia Gravis (gMG) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This ‘Generalized Myasthenia Gravis (gMG)- Epidemiology Forecast – 2032’ report delivers an in-depth understanding of Generalized Myasthenia Gravis (gMG) historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and … [Read more…]

– The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD (“SKATBT-A3”), which measures the effectiveness of the treatment on the patient’s overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. – The first efficacy trial using personalized TCM … [Read more…]